235 related articles for article (PubMed ID: 12389067)
1. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
Junghard O; Hassan-Alin M; Hasselgren G
Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
[TBL] [Abstract][Full Text] [Related]
2. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers.
Hunt RH; Armstrong D; James C; Chowdhury SK; Yuan Y; Fiorentini P; Taccoen A; Cohen P
Am J Gastroenterol; 2005 Sep; 100(9):1949-56. PubMed ID: 16128938
[TBL] [Abstract][Full Text] [Related]
3. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole.
Sostek MB; Chen Y; Andersson T
Br J Clin Pharmacol; 2007 Sep; 64(3):386-90. PubMed ID: 17425628
[TBL] [Abstract][Full Text] [Related]
4. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
[TBL] [Abstract][Full Text] [Related]
5. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
[TBL] [Abstract][Full Text] [Related]
6. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study.
Katz PO; Castell DO; Chen Y; Andersson T; Sostek MB
Aliment Pharmacol Ther; 2004 Aug; 20(4):399-406. PubMed ID: 15298633
[TBL] [Abstract][Full Text] [Related]
7. Acid control with esomeprazole and lansoprazole: a comparative dose-response study.
Wilder-Smith C; Lind T; Lundin C; Nauclér E; Nilsson-Pieschl C; Röhss K
Scand J Gastroenterol; 2007 Feb; 42(2):157-64. PubMed ID: 17327934
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease.
Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):530-7. PubMed ID: 18030229
[TBL] [Abstract][Full Text] [Related]
9. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
[TBL] [Abstract][Full Text] [Related]
10. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
11. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
Morelli G; Chen H; Rossiter G; Rege B; Lu Y
Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
[TBL] [Abstract][Full Text] [Related]
12. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease.
Simon B; Müller P; Pascu O; Gatz G; Sander P; Huber R; Mascher H
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):791-9. PubMed ID: 12811310
[TBL] [Abstract][Full Text] [Related]
13. Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study.
Ullah MA; Shams-Ud-Dowla ; Maruf AA; Azad MA; Shohag MH; Sultana R; Latif AH; Hasnat A
Clin Ther; 2010 Jul; 32(7):1419-26. PubMed ID: 20678688
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous esomeprazole 40 mg and pantoprazole 40 mg on intragastric pH in healthy subjects. A prospective, open, randomised, two-way cross-over comparative study.
Piccoli F; Ory G; Hadengue A; Beglinger C; Degen L
Arzneimittelforschung; 2007; 57(10):654-8. PubMed ID: 18074759
[TBL] [Abstract][Full Text] [Related]
15. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study.
Thomson AB; Cohen P; Ficheux H; Fiorentini P; Domagala F; Homerin M; Taccoen A
Aliment Pharmacol Ther; 2006 Apr; 23(8):1179-87. PubMed ID: 16611279
[TBL] [Abstract][Full Text] [Related]
18. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
[TBL] [Abstract][Full Text] [Related]
19. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
Periclou AP; Goldwater R; Lee SM; Park DW; Kim DY; Cho KD; Boileau F; Jung WT
Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers.
Galmiche JP; Sacher-Huvelin S; Bruley des Varannes S; Vavasseur F; Taccoen A; Fiorentini P; Homerin M
Aliment Pharmacol Ther; 2005 Mar; 21(5):575-82. PubMed ID: 15740541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
